Looking for how many Scam and just horrible projects, it is very difficult to believe in the success of the ICO, but I still believe there are excellent ones.
I think the problem is that many people just fall for marketing instead of carefully checking that a project is based on something solid and contrete. It's really baffling to me how many people invest in bubble soap projects that are just a collection of fancy presentations and are not solving any real issue. We are a biotech company performing novel biomedical research, and one of the things that sets
our ICO apart from the other ICO offerings is that it is based on our AIDS cure research. Behind our project there are therefore many years of hard work and investments to perform and publish our research. Investors with us know that they are investing into something real and concrete, as they can easily verify that our project is something real and legit by checking the publications on the NIH database pubmed.
Fior J. An Initial In Vitro Investigation into the Potential Therapeutic Use of SupT1 Cells to Prevent AIDS in HIV-Seropositive Individuals. PLoS ONE. 2012;7(5):e37511.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22701517Fior J. Is a pacific coexistence between virus and host the unexploited path that may lead to an HIV functional cure? Viruses. 2013;5(2):753-7.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23430684Fior J. Salamander regeneration as a model for developing novel regenerative and anticancer therapies. J Cancer. 2014;5(
:715-9.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25258653Fior J. SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice. Vaccines. 2016;4(2):13.
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27128948Moreover, we are working on solving a real global issue such as developing a low cost cure solution for AIDS. There were 36.7million people infected by HIV globally in 2016, 17.5million of which were left untreated, according to UNAIDS. Our mission is to develop a low cost cell-based therapy solution for HIV to allow access to the treatment for those individuals who are normally left untreated due to social and/or economic limitations. We are getting a lof of interest from venture capitalists as they do not fall for marketing and only invest in solid projects.